Twist Bioscience and Element Biosciences Collaborate on Exome Sequencing Solutions for AVITI System
07 February 2024 - 12:05AM
Business Wire
Twist for Element, Exome 2.0 plus Comprehensive
Exome Spike-in Workflow expected to be available soon
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling
customers to succeed through its offering of high-quality synthetic
DNA using its silicon platform, and Element Biosciences, Inc.,
developer of pioneering technologies to empower science, today
announced a collaboration to develop the Twist for Element, Exome
2.0 plus Comprehensive Exome Spike-in Workflow for Element’s AVITI™
System.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240206284355/en/
“Element continues to expand its customer base, bringing high
quality and cost-effective sequencing to researchers globally.
Pairing Twist’s robust NGS workflows with Element’s AVITI
technology will offer customers an economical and streamlined
approach to next generation sequencing,” said Emily M. Leproust,
Ph.D., CEO and co-founder of Twist Bioscience. “Because our tools
are sequencer agnostic, we can extend the reach of our products
with innovative companies like Element, and continue our commitment
to empowering researchers to accelerate breakthroughs in scientific
discovery by providing advanced tools.”
“We’ve laid out an ambitious product roadmap for 2024 to
redefine what is possible on a sequencer and make it even easier
for labs to produce the highest quality data at a low cost,” said
Molly He, Ph.D., CEO and co-founder of Element Biosciences. “With
the Twist for Element Exome Workflow, we are able to provide our
customers with easy access to Twist’s Exome 2.0 panel and high
performing library preparation and target enrichment reagents,
saving them potential downstream sequencing costs by reducing per
sample sequencing requirements.”
The Twist for Element Exome Workflow is a purpose-built solution
for Element’s AVITI chemistry, alleviating the need for additional
workflow steps for linear library conversion. The workflow will
include Twist’s library preparation and target enrichment bundled
with the Exome 2.0 and comprehensive spike-in. The Exome 2.0
delivers best-in-class sequencing due to its high uniformity and
low off-target rate. It is designed to detect rare and inherited
diseases, as well as germline cancers.
If interested in learning more about the Twist for Element,
Exome 2.0 plus Comprehensive Exome Spike-in Workflow, please reach
out here.
About Element Biosciences, Inc.
Element Biosciences is a multi-disciplinary life science company
focused on developing disruptive DNA sequencing and other omics
technology for research markets. Through innovating every
fundamental element of a sequencing system, Element empowers
customers with affordable, high-quality data and an improved user
experience, which in turn will accelerate scientific discoveries
and broaden the use of genomic research. To learn more about
Element, please visit www.elementbiosciences.com and follow us on
LinkedIn and Facebook.
About Twist Bioscience Corporation
Twist Bioscience is a leading and rapidly growing synthetic
biology and genomics company that has developed a disruptive DNA
synthesis platform to industrialize the engineering of biology. The
core of the platform is a proprietary technology that pioneers a
new method of manufacturing synthetic DNA by “writing” DNA on a
silicon chip. Twist is leveraging its unique technology to
manufacture a broad range of synthetic DNA-based products,
including synthetic genes, tools for next-generation sequencing
(NGS) preparation, and antibody libraries for drug discovery and
development. Twist is also pursuing longer-term opportunities in
digital data storage in DNA and biologics drug discovery. Twist
makes products for use across many industries including healthcare,
industrial chemicals, agriculture and academic research.
Follow us on Twitter | Facebook | LinkedIn | YouTube |
Instagram
Twist Bioscience Legal Notice Regarding Forward-Looking
Statements
This press release contains forward-looking statements. All
statements other than statements of historical facts contained
herein are forward-looking statements reflecting the current
beliefs and expectations of management made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995, including, but not limited to, statements regarding the
ability of the Twist for Element, Exome 2.0 plus Comprehensive
Exome Spike-in Workflow to save researchers potential downstream
sequencing costs by reducing per sample sequencing requirements.
Forward-looking statements involve known and unknown risks,
uncertainties, and other important factors that may cause Twist
Bioscience’s actual results, performance, or achievements to be
materially different from any future results, performance, or
achievements expressed or implied by the forward-looking
statements. Such risks and uncertainties include, among others, the
ability to achieve the expected benefits of Twist Bioscience’s
restructuring activities and reduced investments in DNA data
storage; the ability to attract new customers and retain and grow
sales from existing customers; the ability of Twist Bioscience to
achieve sufficient revenue to achieve or maintain positive cash
flow from operations or profitability in any given period; risks
and uncertainties of rapidly changing technologies and extensive
competition in synthetic biology that could make the products Twist
Bioscience is developing obsolete or non-competitive; uncertainties
of the retention of significant customers; the ability of Twist
Bioscience to successfully integrate acquired companies and to
achieve expected benefits from acquisitions; supply chain and other
disruptions; risks of third party claims alleging infringement of
patents and proprietary rights or seeking to invalidate Twist
Bioscience’s patents or proprietary rights; and the risk that Twist
Bioscience’s proprietary rights may be insufficient to protect its
technologies. For a description of the risks and uncertainties that
could cause actual results to differ from those expressed in these
forward-looking statements, as well as risks relating to Twist
Bioscience’s business in general, see Twist Bioscience’s risk
factors set forth in Twist Bioscience’s Quarterly Report on Form
10-Q filed with the Securities and Exchange Commission on February
2, 2024 and subsequent filings with the SEC. Any forward-looking
statements contained in this press release speak only as of the
date hereof, and Twist Bioscience specifically disclaims any
obligation to update any forward-looking statement, whether as a
result of new information, future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240206284355/en/
For Element Biosciences: Kristi Heim
kristi.heim@elembio.com
For Twist Bioscience:
For Investors: Angela Bitting SVP, Corporate Affairs
925-202-6211 abitting@twistbioscience.com
For Media: Amanda Houlihan Communications Manager
774-265-5334 ahoulihan@twistbioscience.com
Twist Bioscience (NASDAQ:TWST)
Historical Stock Chart
From Jun 2024 to Jul 2024
Twist Bioscience (NASDAQ:TWST)
Historical Stock Chart
From Jul 2023 to Jul 2024